FDA priority review advances belzutifan plus pembrolizumab in adjuvant RCC
Decision brief
Answer first · skim in under a minute
The FDA granted priority review to supplemental applications for belzutifan plus pembrolizumab in adjuvant renal cell carcinoma. The move extends Merck’s renal cancer catalyst path after evidence showed improved disease-free survival versus pembrolizumab alone.
Belzutifan FDA approval on June 12, 2026 adds Welireg to pembrolizumab for adjuvant clear cell renal cell carcinoma after nephrectomy. The decision rests on LITESPARK-022, where the combination cut recurrence, metastasis, or death risk by 28% versus pembrolizumab plus placebo (HR 0.72).
Contents9 sections
Key Takeaways
- Belzutifan FDA approval covers adjuvant ccRCC at intermediate-high or high recurrence risk after nephrectomy, with Keytruda or Keytruda Qlex.
- LITESPARK-022 (NCT05239728) enrolled 1,841 patients; DFS hazard ratio was 0.72 (95% CI 0.59–0.87; p=0.0003).
- Median DFS was not reached; overall survival data were immature at the interim analysis.
- Belzutifan is an oral HIF-2α inhibitor; recommended dosing follows the Welireg label (120 mg once daily in the adjuvant setting per FDA materials).
What did Belzutifan FDA approval change?
On June 12, 2026, FDA approved belzutifan with pembrolizumab or with Keytruda Qlex for adults with renal cell carcinoma with a clear cell component at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. The agency’s summary is posted on the FDA belzutifan adjuvant RCC page.
What did LITESPARK-022 show?
Efficacy came from LITESPARK-022, a multicenter, double-blind, randomized trial in 1,841 patients after nephrectomy for clear cell RCC. The primary endpoint was investigator-assessed disease-free survival (time to recurrence, metastasis, or death).
- 186 DFS events with belzutifan plus pembrolizumab versus 246 with placebo plus pembrolizumab
- Hazard ratio 0.72 (95% CI 0.59–0.87); p=0.0003
- Median DFS not reached in either arm
- Overall survival immature at the prespecified interim analysis
Trial registration is available on ClinicalTrials.gov NCT05239728.
How does this fit prior adjuvant Keytruda use?
Adjuvant pembrolizumab was already a standard option after KEYNOTE-564 for higher-risk clear cell RCC. Belzutifan FDA approval layers a HIF-2α inhibitor onto that backbone for selected intermediate-high and high-risk patients. Sponsor context is summarized in Merck’s Business Wire release on the combination approvals.
What should BD and clinical teams watch?
Teams should track label language for risk strata, companion dosing with Keytruda Qlex, Project Orbis partner decisions, and mature overall survival. Related NovaPharma coverage includes the parallel approval note and prior Opdivo RCC context for competitive framing.
Sponsor disclosure is also available via Merck’s June 2026 announcement.
What remains unproven
Overall survival benefit is not yet established. Cross-trial comparisons with other adjuvant regimens are not definitive. Real-world adherence to oral belzutifan plus intravenous or subcutaneous pembrolizumab schedules will need post-marketing evidence.
Related NovaPharma coverage
- FDA approves belzutifan plus pembrolizumab for adjuvant RCC
- FDA Approves Opdivo for Advanced Renal Cell Carcinoma
- FDA Approves Capivasertib for PTEN-Deficient Prostate Cancer
Frequently Asked Questions
What did the Belzutifan FDA approval cover on June 12, 2026?
The FDA approved belzutifan (Welireg) with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for adjuvant treatment of adults with clear cell renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy plus resection of metastatic lesions.
What trial supported Belzutifan FDA approval in adjuvant RCC?
LITESPARK-022 (NCT05239728) enrolled 1,841 patients after nephrectomy for clear cell RCC. Belzutifan plus pembrolizumab improved disease-free survival versus placebo plus pembrolizumab (hazard ratio 0.72; 95% CI 0.59–0.87; p=0.0003). Median DFS was not reached in either arm; overall survival data were immature.
Was Belzutifan FDA approval reviewed under priority review?
Yes. The supplemental applications received priority review before the June 12, 2026 approval, and FDA reviewed the package under Project Orbis with international partners.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for belzutifan.
Unlock full calendar →Merck & Co., Inc. pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
